Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

Topical Application of ASN008, a Permanently-charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset and Long Duration of Action in a Mouse Model of Pruritus

Roshni Ramachandran, Scott K. Thompson, Shelle Malkmus, Sandeep Gupta, Tsutomu Mieda, Jun-Hsiang Lin and Tony L Yaksh
Journal of Pharmacology and Experimental Therapeutics July 2, 2020, jpet.120.265074; DOI: https://doi.org/10.1124/jpet.120.265074
Roshni Ramachandran
1 Department of Anesthesiology, UCSD, 214 Dickenson Street, San Diego, CA 92103, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott K. Thompson
2 Asana BioSciences, 1997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, NJ 0;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelle Malkmus
1 Department of Anesthesiology, UCSD, 214 Dickenson Street, San Diego, CA 92103, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Gupta
2 Asana BioSciences, 1997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, NJ 0;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsutomu Mieda
3 UC San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun-Hsiang Lin
2 Asana BioSciences, 1997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, NJ 0;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony L Yaksh
3 UC San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tony L Yaksh
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The sensation of pruritus, or itch, is associated with a variety of skin and medical disorders. Itch is transmitted through afferent C-fibers, and sodium channels play a key role in the transmission process. Local anesthetics, which block sodium channels, are used topically to treat itch, but generally have a short duration of action and are not selective for afferent nerves underlying the itch sensation. Accordingly, there is a substantial unmet need for safe, efficacious, long-acting treatments for chronic pruritus, including non-histaminergic itch. We investigated the dose-response, time to onset and duration of action of ASN008 topical gel, which targets small afferent sodium channels, in a murine model of pruritus in which scratching behavior is induced by intradermal injection of chloroquine into the nape of the neck of C57BL/6 mice. Topical application of ASN008 gel resulted in a concentration-dependent reduction of scratching behavior. Onset of action was ≤ 1 hour and duration of scratching inhibition was 15-24 hours. In a further study involving once-daily application for 5 days with chloroquine challenge on day 5, treatment with ASN008 gel again resulted in a concentration-dependent reduction of chloroquine-induced scratching, even when the gel was removed 3 hours after each daily application. In conclusion, topical ASN008 gel produces a dose-dependent reduction of scratching in a mouse model of pruritus, with a rapid onset and long duration of action, and may prove to be an effective, once-daily treatment for a variety of pruritic conditions in humans, including non-histaminergic itch.

SIGNIFICANCE STATEMENT ASN008 gel produces a dose-dependent reduction of scratching in a mouse model of pruritus, with a rapid onset and long duration of action, and may prove to be an effective, once or twice-daily treatment for a variety of pruritic conditions in humans, including non-histaminergic itch. ASN008 topical gel is currently under investigation in Phase 1 clinical studies to evaluate safety, tolerability, pharmacokinetics and preliminary anti-pruritic efficacy in atopic dermatitis patients (ClinicalTrials.gov ID: NCT03798561).

  • immunopharmacology
  • inflammation
  • pain
  • pharmacokinetics
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 1
1 Apr 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Topical Application of ASN008, a Permanently-charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset and Long Duration of Action in a Mouse Model of Pruritus
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

Topical Application of ASN008, a Permanently-charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset and Long Duration of Action in a Mouse Model of Pruritus

Roshni Ramachandran, Scott K. Thompson, Shelle Malkmus, Sandeep Gupta, Tsutomu Mieda, Jun-Hsiang Lin and Tony L Yaksh
Journal of Pharmacology and Experimental Therapeutics July 2, 2020, jpet.120.265074; DOI: https://doi.org/10.1124/jpet.120.265074

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleInflammation, Immunopharmacology, and Asthma

Topical Application of ASN008, a Permanently-charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset and Long Duration of Action in a Mouse Model of Pruritus

Roshni Ramachandran, Scott K. Thompson, Shelle Malkmus, Sandeep Gupta, Tsutomu Mieda, Jun-Hsiang Lin and Tony L Yaksh
Journal of Pharmacology and Experimental Therapeutics July 2, 2020, jpet.120.265074; DOI: https://doi.org/10.1124/jpet.120.265074
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PK/PD of Dexamethasone in LPS-Challenged Rats
  • Expression of PAR2 in iKera to Model Atopic Dermatitis
  • Cholesterol Esterification and Acute Lung Injury
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics